Medecins Sans Frontieres interventions against kala-azar in the Sudan, 1989-2003

被引:25
作者
Ritmeijer, K. [1 ]
Davidson, R. N. [1 ,2 ]
机构
[1] Med Sans Frontiers Holland, NL-1001 EA Amsterdam, Netherlands
[2] Northwick Pk Hosp & Clin Res Ctr, Dept Infect & Trop Med, Harrow, Middx, England
关键词
visceral leishmaniasis; Leishmania donovani; humanitarian aid; antimonials; Sudan;
D O I
10.1016/S0035-9203(03)80047-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Since 1989, Medecins Sans Frontieres (MSF) has provided medical humanitarian assistance during outbreaks of visceral leishmaniasis (VL; kala-azar) in Sudan. First, in western Upper Nile in southern Sudan, where a VL epidemic occurred after the resumption of the civil war in Sudan in 1983, with an estimated 100 000 deaths. Later, MSF started interventions in eastern Upper Nile and Gedaref State. In these 2 endemic regions VL incidence has risen markedly since 2001, which could be the start of a new epidemic cycle. Outbreaks of VL in Sudan remain unpredictable, and access to affected populations in war-torn southern Sudan is often hampered by insecurity. Therefore, MSF takes a flexible approach, establishing treatment centres where patients can be accessed. From 1989 to 2002, MSF treated > 51 000 VL cases in Sudan. Despite very basic field conditions, high cure rates of 95% are being achieved. Lack of diagnostics is a major obstacle to treatment, especially during epidemic situations. Therefore, development of simple and rapid technologies is required, allowing reliable diagnosis under field conditions. For treatment of VL there is a limited choice of effective, affordable drugs. There are strong indications of an emerging resistance to antimonials in Malakal. Introduction of combination therapies is urgently needed to prevent the further emergence and spread of resistance to antimonials, which are still the mainstay of VL treatment in eastern Africa. Experience with combination therapy with sodium stibogluconate (SSG) and paromomycin is promising, and combinations of SSG with liposomal amphoteriein B and miltefosine are currently being explored.
引用
收藏
页码:609 / 613
页数:5
相关论文
共 21 条
[1]   rK39: A cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis [J].
Badaro, R ;
Benson, D ;
Eulalio, MC ;
Freire, M ;
Cunha, S ;
Netto, EM ;
PedralSampaio, D ;
Madureira, C ;
Burns, JM ;
Houghton, RL ;
David, JR ;
Reed, SG .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (03) :758-761
[2]  
DEBEER P, 1990, LANCET, V335, P224, DOI 10.1016/0140-6736(90)90313-T
[3]   Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan [J].
Griekspoor, A ;
Sondorp, E ;
Vos, T .
HEALTH POLICY AND PLANNING, 1999, 14 (01) :70-76
[4]  
Harith AE, 1988, J CLIN MICROBIOL, V26, P1321
[5]  
Moore E, 2001, B WORLD HEALTH ORGAN, V79, P388
[6]  
*MSF, 2002, VIOL HLTH ACC AID US
[7]  
*MSF, 2003, MSF MAN DIAGN TREATM
[8]  
PEREA WA, 1989, LANCET, V2, P1222, DOI 10.1016/S0140-6736(89)91834-5
[9]   Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome [J].
Ritmeijer, K ;
Veeken, H ;
Melaku, Y ;
Leal, G ;
Amsalu, R ;
Seaman, J ;
Davidson, RN .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2001, 95 (06) :668-672
[10]   EPIDEMIC VISCERAL LEISHMANIASIS IN SUDAN - A RANDOMIZED TRIAL OF AMINOSIDINE PLUS SODIUM STIBOGLUCONATE VERSUS SODIUM STIBOGLUCONATE ALONE [J].
SEAMAN, J ;
PRYCE, D ;
SONDORP, HE ;
MOODY, A ;
BRYCESON, ADM ;
DAVIDSON, RN .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (03) :715-720